BTG Share Price (BTG)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
BTG Plc	LSE:BTG	London	Ordinary Share	GB0001001592	ORD 10P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+6.50p	+1.22%	538.50p	769,793	16:35:23
Bid Price		Offer Price	High Price	Low Price	Open Price
537.00p		537.50p	543.50p	521.00p	530.00p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Support Services	620.5	-70.6	3.9	138.1	2,085.69

Related Shares
Experian (EXPN), Ferguson (FERG), Servision (SEV), Nakama (NAK)

BTG (BTG) Latest News

BTG News

Date	Time	Source	Headline
21/6/2018	14:07	BW	PERT Consortium and BTG Form Strategic Partnership
19/6/2018	16:43	UKREG	BTG PLC Director/PDMR Shareholding
19/6/2018	12:13	UKREG	BTG PLC Historical Financial Information Restated to USD
18/6/2018	14:42	UKREG	BTG PLC Annual Financial Report
18/6/2018	09:35	UKREG	BTG PLC Holding(s) in Company
15/6/2018	08:15	ALNC	TOP NEWS: BTG Fails To Gain FDA Panel Support For Emphysema Treatment
15/6/2018	07:12	ALNCF	Alliance News Flash Headline
15/6/2018	07:00	RNSNON	BTG PLC Result of FDA Advisory Committee vote on Elevair
12/6/2018	16:46	UKREG	BTG PLC Holding(s) in Company
11/6/2018	16:11	UKREG	BTG PLC Director/PDMR Shareholding

More BTG News

BTG Takeover Rumours

BTG (BTG) Share Charts

1 Year BTG Chart

1 Month BTG Chart

Intraday BTG Chart

BTG (BTG) Discussions and Chat

BTG Forums and Chat

Date	Time	Title	Posts
21/6/2018	21:30	BTG	5,489
12/11/2013	08:46	BTG down the tube	6
09/3/2012	07:16	Bright Things	3
10/9/2004	20:24	Varisolve hits the FDA buffer's	6

Add a New Thread

BTG (BTG) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all BTG trades in real-time

BTG (BTG) Top Chat Posts

Date	Subject
23/6/2018 09:20	BTG Daily Update: BTG Plc is listed in the Support Services sector of the London Stock Exchange with ticker BTG. The last closing price for BTG was 532p. BTG Plc has a 4 week average price of 482.40p and a 12 week average price of 482.40p. The 1 year high share price is 784p while the 1 year low share price is currently 482.40p. There are currently 387,314,436 shares in issue and the average daily traded volume is 1,428,909 shares. The market capitalisation of BTG Plc is £2,085,688,237.86. Read Full Thread Reply
15/6/2018 11:32	desha: Hi Eastbourne interested to see what you think are near term catalysts to a rising share price? Personally, I can't see any - the unbroken string of bad news in the last year may be considered unlucky but the Board (and esp LM) are paid to manage this. The only positive revenue surprise has been Zytiga, which is due to Johnson & Johnson! Long term holder from Biocompatibles days. Read Full Thread Follow Reply
15/6/2018 08:34	eastbourne1982: Share price is down 2 - 3%, hardly carnage, £3 - £4 looks a long way away. Read Full Thread Follow Reply
15/6/2018 06:30	spyder: Re the Wellstat appeal loss in Delaware, I am a little surprised that BTG haven't released the news to the market given it happened on Monday. I guess it depends on whether this is a regulatory newsworthy event, and that in turn depends on whether the news will move the share price. Again, maybe the outcome has been anticipated, and the fine already provided for, I guess we'll see what happens to the shares, but it could be argued that there has been a false market for the last 4 days with the shares drifting lower. I suppose now it will be difficult to untangle the outcome from the FDA news overnight. Read Full Thread Follow Reply
14/6/2018 10:41	cockneytrader: The FDA meeting is scheduled today, so we will know the outcome tomorrow in an RNS. I believe this will be make or break for the share price. I don't know which way the FDA will vote, but I would imagine they will want to see the data from the recently announced ELEVATE trial. Read Full Thread Follow Reply
16/6/2017 11:54	aphrodites: Having suffered a DVT myself a couple of years ago in my right leg and with a vein from my knee to my groin now blocked for life, I am probably more aware than most about the advantages the treatment with the EKOS system will provide to the medical world. The present treatment to unblock veins is very primitive and the success rate very, very low indeed. The damage caused to the valves in veins is irreparable unless the blockage is cleared very quickly. The market for the treatment of DVTs is massive and contrary to general opinion the condition is not restricted just to the elderly. I am reliably informed by an air hostess that a young lady of 34 y.o.a suffered a DVT on a flight and actually died on the plane. DVT's are very common indeed. I did have the statistics somewhere but cannot put my hands on them. Maybe someone else can provide. The announcement today has in my opinion far greater implications to the BTG share price than is fully appreciated and I am surprised the price is not back over £7 and moving higher. But it is a Friday. Obviously we will have to wait for the analysts to digest the news and get the blue pencils out next week. Have a good weekend everyone. Onwards and upwards. Read Full Thread Follow Reply
13/6/2017 20:01	aphrodites: fhmktg You should breath in again and wait for news possibly on the 15th which could be very important for the share price. And as for Crofab why not update everyone with the news released today, not massive but nevertheless interesting and was not the reason for today's price rise??????????? New Study Shows Patients Treated With CroFab® Have Improved Recovery From Copperhead Envenomation PHILADELPHIA, June 13, 2017 /PRNewswire/ -- A study sponsored by BTG plc (LSE: BTG), the global specialist healthcare company, has been recently published in the Annals of Emergency Medicine (AEM) that shows administering CroFab® to patients envenomated by copperhead snakes can aid the recovery of a patient's affected limb function as compared with placebo. (Logo: hxxp://photos.prnewswire.com/prnh/20150805/255981LOGO ) The randomised, double-blind, placebo-controlled study compared CroFab® Crotalidae Polyvalent Immune Fab (Ovine) - the only antivenom currently marketed for the treatment of crotaline snake envenomation - against placebo for the treatment of copperhead snake envenomation for the first time. Copperhead envenomation is generally considered less severe than other North American Pit Viper snakebites, but more than 95% of copperhead victims still develop significant pain and swelling of the injured limb, and other soft tissue injury. Most patients resume activities within 2-4 weeks but residual symptoms can last for a year. Dr Charles Gerardo, Chief of Emergency Medicine at Duke University and expert in Copperhead snake envenomation, said: "For the first time, this data demonstrates that CroFab® improves recovery of limb function from Copperhead envenomation. Additionally, antivenom treatment was associated with less opioids use throughout the patient's recovery. These results can be used to help physicians and patients make a more informed choice about their care." In total, 74 patients participated in the study; 45 were treated with CroFab® and the rest received a placebo. All participating trial staff (apart from the study pharmacist) and patients were unaware of the treatment given in each case. Within the patient cohort was a mix of upper and lower extremity conditions depending on where the copperhead had bitten the patient. The Patient Specific Functional Scale (PSFS) was used to measure study outcomes by assessing each patient's ability to do daily activities that they were unable to do or had difficulty with post copperhead inflicted injury. The tasks varied from driving a car, climbing the stairs, brushing teeth, or using a cell phone and took in to account the score at envenomation + 14 days using a 0-10 scale. In addition to the positive primary outcome of the study, it was also discovered that opioid analgesic use was less in CroFab® treated patients. Dan Schneider, SVP and General Manager, Specialty Pharmaceuticals, Commercial Operations at BTG, said: "We are pleased with the clinical study findings that show that patients treated with CroFab® recover faster from Copperhead bites. Even though we haven't reached summer months yet, we are seeing multiple reports stating that the frequency of bites in the U.S. are on the rise this year. As snake sightings start to pick up, don't forget to download our free, educational SnakeBite911™ App Suite. It has useful information about the dos and don'ts if envenomation occurs and helps raise awareness about North American Pit Vipers." To review the published article in full, please refer to the following link: hxxp://www.annemergmed.com/article/S0196-0644(17)30510-3/fulltext. Indication CroFab® Crotalidae Polyvalent Immune Fab (Ovine) is a sheep-derived antivenin indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins. Important Safety Information The most common adverse reactions reported in the clinical studies were urticaria, rash and nausea. Adverse reactions involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 12 of the 42 patients. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment and one patient discontinued CroFab® due to an allergic reaction. Anaphylaxis and hypersensitivity reactions can occur, and patients should be monitored closely during treatment. CroFab® should not be administered to patients with a known history of hypersensitivity to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available. In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets and elevated prothrombin time, occurred in approximately half of the patients studied; one patient required rehospitalization and additional antivenin administration. Recurrent coagulopathy may persist for 1 to 2 weeks or more. Patients who experience coagulopathy due to snakebite should be monitored for recurrent coagulopathy for up to 1 week or longer. During this period, the physician should carefully assess the need for re-treatment with CroFab® and use of any type of anticoagulant or anti-platelet drug. About BTG BTG is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: btgplc.com. For further information contact: BTG Andy Burrows, VP Corporate & Investor Relations Read Full Thread Follow Reply
10/5/2017 08:38	aphrodites: bargainbob BTG is not about always delivering blockbuster products. It is a relatively “young” company and as it states it is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. Its portfolio today already highlights its specialisation in Interventional Medicine and as it success grows so will its reputation to attract and help develop many more new blockbusting products to take to the market. Of course there will be disappointments along the way but that is always a feature and factor you have to build into the line of business it is in. I mentioned £20 as a target price for the future. That is not my expectation for tomorrow. But with a company like this, successful new innovations can deliver surprises in a share price that one never anticipated. As you are probably aware, BTG is a favourite of Fund Manager Neil Woodford. Last year he was reported as saying: “BTG currently resides in the FTSE 250 but my guess is that growing cash generation will end up propelling the fast-growing enterprise into the top index one day. In a recent update, BTG revealed double-digit revenue growth as it continues to make progress with several products.” Right now, BTG doesn’t pay a dividend but the firm’s strong cash flow suggests plenty of potential to do so down the road. In the meantime, investors will likely enjoy share-price growth as long as the company keeps gaining market share. City analysts following BTG predict an uplift of around 37% in earnings per share for the year to March 2018, so growth potential is on the table. Meanwhile, Imperial Brands thinks its earnings will inflate by 12% during the year to September 2017. That’s a good enough reason for me to hold this share in my portfolio and if it does continue to gain market share, the expectation of £20 down the road becomes more than a reality. Read Full Thread Follow Reply
13/10/2015 11:54	cyman: well the last sell recommendation to 565 (I think it was) proved to be a huge success and we were all laughing at it when we were basking in the sunshine of 800p. btg share price reactions of the past have often proven themselves to have been huge over-reactions - like when Louise settled her divorce, everyone was accusing her of all manner of sorcery - so hopefully this too was nothing more than an over reaction and we can start to settle back into the 600's whilst we await next years forecasts etc. Read Full Thread Follow Reply
21/6/2015 12:08	spyder: Here are my thoughts on what is happening with the BTG share price, for what they are worth. I suggested in posts to this board several times in the last few months, and most recently at around the time of the results, that the BTG share price was approaching very dangerous chart territory. If it failed to rally, then there would be no support for the shares going forward. Unfortunately, I didn’t “put my money where my mouth was”, because subsequent events proved my comments to be correct and the shares have dropped approximately 20% in the last month or so. I’m afraid the news doesn’t get any better, as, again looking at the chart, this share only has one way to go, and it will continue falling. There could be support at £6.00, and again at £5.00, but I won’t be around to see £5.00 tested if that were to happen and I have an opportunity to exit. To those of you who think charts are nonsense and it is all about the fundamentals, I say that the charts have called it absolutely right so far, in spite of broadly unchanged fundamentals. Indeed, looking at BTGs own forecasts, and almost universally those of the analysts, the outlook remains a positive as ever, so why the freefall? And where are the value buyers? The next few weeks will be a classic test of predicting share price by chart vs fundamentals. If the chart wins, we are heading lower, perhaps significantly. If the fundamentals are to be believed, then value investors should pile in before long. My own strategy is to continue holding, because my investment timeframe is 5 to 10 years, so perhaps one day this will be seen as just another pothole on the road to the FTSE 100. HOWEVER, if the shares fall to £5.80 and linger for more than a day or so, I’m out. Unfortunately I have seen too many extremely successful shares tank for no reason given the fundamentals, only to see that the fundamentals turned out to be hot air. The market (and the chart) usually (but not always!) knows best. Read Full Thread Follow Reply
30/3/2015 18:47	a1ord53: We Could Be Seeing A Buying Opportunity With Fast-Growers ARM Holdings plc And BTG plc By Motley Fool \| Mon, 30th March 2015 - 09:16 Share this Markets go neither up nor down in straight lines. Every so often, rising share prices suffer a market 'correction' that could end up being nothing more than a brief interruption in upward progress. Not every reversal becomes a bear market If a firm's trading fundamentals don't change and the economic environment remains steady, there's every chance that lower share prices add up to nothing more than market jitters. Such share price reversals, as long as they prove to be temporary, could provide a better value buying opportunity as decent, well-performing companies sell for a lower price on the stock market. The 'trick' for us investors is to make sure a firm's underlying prospects haven't changed and that the valuation still makes sense. If those things seem in order, there's no reason to be shy about buying. Indeed, if we don't buy on market dips, when do we buy? Today, let's take a closer look at two companies with strong forecast earnings growth that have seen their share prices fall in the last few days, ARM Holdings (LSE:ARM) and BTG (LSE:BTG). Upbeat outlook On 11 February, chip designer ARM Holdings posted encouraging fourth-quarter results with strong revenue and growth in earnings. Back then, the chief executive said the firm saw strong licence revenue growth all through 2014, driven by market-leading semiconductor companies increasing their commitment to use ARM technology and a broadening range of new customers choosing ARM technology for the first time. The rate of growth for ARM's royalty revenue even increased during the fourth quarter. The top man reckons 2015 will be a year of exciting opportunities and challenges as ARM invests in new products and technologies, and continues to establish itself in competitive new markets. The firm continues to gain market share and, as chips based on ARMv8-A processors and Mali graphics IP start shipping in higher volumes, the outlook for royalty revenues in 2015 and beyond is encouraging, he says. Yet despite such a bright outlook, ARM Holdings' share price still sold off from recent highs around 1200p over the last few days to follow the stumbles of tech shares across the pond in the US. Can so much have changed for ARM's prospects since February, or is this little trip-up a good time for investors to top up? Exceeding expectations As I write, speciality pharmaceuticals company BTG (LSE:BTG) is also down, in excess of 15% from the 828p or so the share price achieved at the beginning of the year. The firm's overall performance during the year to date has been in line with the directors' expectations, they said, back in February with the interim results release. There's been an upgrade along the way with the company targeting full-year revenue in the range £345m-£360m, up from estimates of £330m to £345m. All seems well. BTG is a growing international specialist healthcare company that is developing and commercialising products targeting acute care, cancer and vascular diseases. The pharmaceutical sector has great longer-term fundamentals and clear growth drivers, and BTG occupies a sweet spot within the industry. The company enjoys diversified revenues from sales of self-marketed products and from royalties on partnered products. Forward earnings-growth projections remain robust. Perhaps it's the US economic growth figures spooking the market a little. A cooling in the fourth quarter saw general after-tax corporate profits record a drop as a strong dollar dented the earnings of multinational corporations. Who knows? There's always something to worry about as bull markets usually climb a wall of worry. Kevin Godbold owns shares in ARM Holdings and BTG. The Motley Fool UK has recommended ARM Holdings and BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Read Full Thread Follow Reply

BTG share price data is direct from the London Stock Exchange

add chat code

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:30 V: D:20180623 21:36:39